Lipoprotein-associated phospholipase A2: The story continues
文献类型：期刊论文
| 作者 | Huang, Fubao1,2; Wang, Kai1; Shen, Jianhua1
|
| 刊名 | MEDICINAL RESEARCH REVIEWS
 |
| 出版日期 | 2020 |
| 卷号 | 40期号:1页码:79-134 |
| 关键词 | fragment-based lead discovery inflammation inhibitors lipoprotein-associated phospholipase A2 vascular diseases |
| ISSN号 | 0198-6325 |
| DOI | 10.1002/med.21597 |
| 通讯作者 | Wang, Kai(kwang@simm.ac.cn) ; Shen, Jianhua(jhshen@simm.ac.cn) |
| 英文摘要 | Inflammation is thought to play an important role in the pathogenesis of vascular diseases. Lipoprotein-associated phospholipase A2 (Lp-PLA2) mediates vascular inflammation through the regulation of lipid metabolism in blood, thus, it has been extensively investigated to identify its role in vascular inflammation-related diseases, mainly atherosclerosis. Although darapladib, the most advanced Lp-PLA2 inhibitor, failed to meet the primary endpoints of two large phase III trials in atherosclerosis patients cotreated with standard medical care, the research on Lp-PLA2 has not been terminated. Novel pathogenic, epidemiologic, genetic, and crystallographic studies regarding Lp-PLA2 have been reported recently, while novel inhibitors were identified through a fragment-based lead discovery strategy. More strikingly, recent clinical and preclinical studies revealed that Lp-PLA2 inhibition showed promising therapeutic effects in diabetic macular edema and Alzheimer's disease. In this review, we not only summarized the knowledge of LpPLA2 established in the past decades but also emphasized new findings in recent years. We hope this review could be valuable for helping researchers acquire a much deeper insight into the nature of Lp-PLA2, identify more potent and selective Lp-PLA2 inhibitors, and discover the potential indications of Lp-PLA2 inhibitors. |
| WOS关键词 | PLATELET-ACTIVATING-FACTOR ; CORONARY-HEART-DISEASE ; ACETYLHYDROLASE PAF-AH ; SINGLE-NUCLEOTIDE POLYMORPHISMS ; ZINC-DEPENDENT INHIBITORS ; PLA2G7 GENE POLYMORPHISMS ; ORALLY-ACTIVE INHIBITORS ; BLOOD-BRAIN-BARRIER ; ACID-LABILE FACTOR ; A(2) LP-PLA(2) |
| 资助项目 | Shanghai Committee of Science and Technology, China[18431901000] ; National Natural Science Foundation of China[81673302] ; National Natural Science Foundation of China[81602963] ; National Science & Technology Major Project 'Key New Drug Creation and Manufacturing Program', China[2018ZX09711002006-014] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000534635500006 |
| 出版者 | WILEY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/280025]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Wang, Kai; Shen, Jianhua |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med SIMM, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 | Huang, Fubao,Wang, Kai,Shen, Jianhua. Lipoprotein-associated phospholipase A2: The story continues[J]. MEDICINAL RESEARCH REVIEWS,2020,40(1):79-134. |
| APA | Huang, Fubao,Wang, Kai,&Shen, Jianhua.(2020).Lipoprotein-associated phospholipase A2: The story continues.MEDICINAL RESEARCH REVIEWS,40(1),79-134. |
| MLA | Huang, Fubao,et al."Lipoprotein-associated phospholipase A2: The story continues".MEDICINAL RESEARCH REVIEWS 40.1(2020):79-134. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。